You just read:

New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

News provided by

Oncopeptides AB

14 Jun, 2019, 09:20 BST